
Virpax Pharmaceuticals’ Probudur Shows Promising Results in Pain Management Study
BERWYN, PA — Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX) has unveiled hopeful results from its Maximum Tolerated Dose (MTD) study of Probudurâ„¢, a long-acting pain management drug, in Sprague-Dawley rats. Probudur, …
Virpax Pharmaceuticals’ Probudur Shows Promising Results in Pain Management Study Read More